Cytotheryx vs Insilico Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bio-incubators for human hepatocyte production at scale.
About
Cytotheryx is a Mayo Clinic spinout developing human hepatocytes (liver cells) produced at scale using genetically engineered pigs as bio-incubators. The company raised $60 million in Series A financing in January 2026 led by Ouroboros Capital, with GMP (Good Manufacturing Practice) manufacturing expansion underway to support both its acute liver failure support program and transplant-grade cell therapy pipeline.
Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.
About
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.